Article
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
25 Apr 2007
Abstract excerpt
Derivative chromosome 9 deletions are seen in 10% to 15% of patients with chronic myelogenous leukemia and have been associated with a poor prognosis; however, no studies have been performed in the context of a randomized clinical trial. We developed a DNA-based deletion screen and investigated 339 chronic phase patients treated with interferon-alpha as first-line therapy in 3 controlled German studies with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.